Prasugrel Delay Could Extend Well Into 2009; FDA Eyes February Cmte. Review
Executive Summary
It looks like FDA's decision on Lilly's anti-clotting drug prasugrel won't come before March 2009 at the earliest
You may also be interested in...
FDA Keen On Lilly’s Prasugrel: Will Advisory Committee Follow Suit?
FDA says that increased risk of bleeding for prasugrel’s clear cardiovascular efficacy is a “reasonable trade.”
Lilly Plays Up Biotech But Major Pipeline Developments Are Long-Term
Eli Lilly's biotech strategy calls for the creation of a pipeline that will yield one new biotechnology-based drug launch each year beginning in 2011, the company announced
Lilly Plays Up Biotech But Major Pipeline Developments Are Long-Term
Eli Lilly's biotech strategy calls for the creation of a pipeline that will yield one new biotechnology-based drug launch each year beginning in 2011, the company announced